D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Randomized phase II study of pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) versus pem alone in patients (pts) with advanced non-small cell lung cancer (NSCLC).
Tianhong Li,Bilal Piperdi,William V. Walsh,Mimi Y. Kim,Rasim Gucalp,Missak Haigentz,Venu Bathini,Xiaoxia Wu,Patricia Pasquinelli,Srikanth Gajavelli,Meera Sreedhara,Laurel A. Beckett,Primo N. Lara,David R. Gandara,Roman Perez-Soler +14 more
TL;DR: It is shown that PDS optimizes cytotoxicity of concurrent EGFR inhibitors and chemotherapy and thereby reduces the likelihood of serious adverse events in patients treated with PDS.
Journal ArticleDOI
Phase II study of ABBV-399 (Process II) in patients with C-MET positive stage IV/recurrent lung squamous cell cancer (SCC): LUNG-MAP sub-study S1400K (NCT03574753).
Saiama N. Waqar,Mary W. Redman,Susanne M. Arnold,Fred R. Hirsch,Philip C. Mack,Lawrence H. Schwartz,David R. Gandara,Tom Stinchcombe,Natasha B. Leighl,Suresh S. Ramalingam,Saloni H. Tanna,Ryan S. Raddin,Katherine Minichiello,Karen Kelly,Jeffrey D. Bradley,Roy S. Herbst,Vassiliki A. Papadimitrakopoulou +16 more
TL;DR: S1400K was designed to evaluate the response to ABBV-399, an antibody-drug conjugate targeting C-MET, in patients treated with Lung-MAP to assess targeted therapies in SCC.
Journal ArticleDOI
O.02: Plasma Next Generation Sequencing of Over 5,000 Advanced Non-Small Cell Lung Cancer Patients With Clinical Correlations
Philip C. Mack,Kimberly C. Banks,Oliver A. Zill,Stefanie Mortimer,Darya Chudova,Justin Odegaard,Christine E. Lee,Rebecca J. Nagy,Helmy Eltoukhy,AmirAli Talasaz,Richard B. Lanman,David R. Gandara +11 more
Journal ArticleDOI
Outcomes for patients treated with or without bevacizumab on SWOG S0819: A randomized, phase III study comparing carboplatin/Paclitaxel or carboplatin/Paclitaxel/bevacizumab with or without concurrent cetuximab in patients with advanced non-small cell lung cancer (NSCLC).
Thomas J. Semrad,Mary W. Redman,Roy S. Herbst,Edward S. Kim,Lyudmila Bazhenova,Gregory A. Masters,Kurt R. Oettel,Perry Guaglianone,Christopher M. Reynolds,Anand B. Karnad,Susanne M. Arnold,Marileila Varella-Garcia,James C. Moon,Philip C. Mack,Charles D. Blanke,Fred R. Hirsch,Karen Kelly,David R. Gandara +17 more
TL;DR: Sub subset analyses were conducted to compare the baseline characteristics and treatment outcomes for Bev-included (BI) versus BE pts, as well as BE subsets defined by the protocol (BE-Inappropriate) or patient/investigator choice ( BE-Choice).
Journal ArticleDOI
A phase I study of cediranib (NSC #732208) in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma (SWOG S0905).
Anne S. Tsao,James C. Moon,Ignacio I. Wistuba,Nicholas J. Vogelzang,Gregory P. Kalemkerian,Mary W. Redman,David R. Gandara +6 more
TL;DR: Based on the toxicity profile, a decision was made to proceed with cediranib 20 mg daily for the remaining phase I/II patients in mesothelioma.